Mirvetuximab soravtansine for resistant ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing a drug called mirvetuximab soravtansine (MIRV) in real-world conditions for people with a specific type of ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see how well the drug works and what side effects occur in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous and resistant to platinum chemotherapy (like carboplatin or cisplatin).
- Your tumor must test positive for a protein called folate receptor-alpha (FRα) at a high level (at least 75% of cells showing moderate to strong staining).
- You must have had between 1 and 3 prior cancer treatments (systemic therapies).
- You must not have any reason you cannot take mirvetuximab soravtansine (per the approved drug label).
- You cannot be currently enrolled in another clinical trial of an investigational drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
This study tests a new combination of two medications for ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the disease down in patients who have limited options left.
Hear when a new Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.